2022-05-10 21:07:23来源：医脉通阅读：12次
医脉通编辑整理，未经授权请勿转载
一年一度的全球肿瘤界盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月3日-7日召开。医脉通对结直肠癌领域的部分重磅研究进展进行了梳理。一起来看下吧！
全体大会
01 摘要号：LBA1
帕尼单抗（PAN）联合mFOLFOX6对比贝伐珠单抗（BEV）联合mFOLFOX6作为RAS野生型（WT）转移性结直肠癌（mCRC）患者的一线治疗：来自III期研究PARADIGM的结果
标题：Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
报告人：Takayuki Yoshino, PhD
单位：National Cancer Center Hospital East
口头报告
01 摘要号：3500
mFOLFOX6或CAPOX围手术期化疗治疗局部晚期结肠癌（OPTICAL）：一项多中心，随机，III期临床试验
标题：Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial.
报告人：胡华斌
单位：中山大学附属第六医院
02 摘要号：3501
TAUTEM的术前，手术和病理结果：直肠癌T2-T3s（浅表）N0，M0（T2T3sN0M0）接受新辅助治疗和局部切除（TEM）与全直肠系膜切除术（TME）的非劣效性多中心前瞻性随机对照研究
标题：Noninferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 (T2T3sN0M0) undergoing neoadjuvant treatment and local excision (TEM) versus total mesorectal excision (TME): Preoperative, surgical, and pathological outcomes—The TAUTEM-study.
报告人：Xavier Serra-Aracil
单位：Corporacion Sanitaria Parc Tauli
03 摘要号：3502
STAR-TREC II期研究：对于早期直肠癌，观察等待或经肛门手术继以（化）放疗相比全系膜切除术能否保肛？
标题：STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?
报告人：Simon Parkinson Bach, MD FRCS
单位：University of Birmingham
04 摘要号：3503
随机间歇或连续帕尼单抗联合FOLFIRI（FOLFIRI/PANI）用于RAS/BRAF野生型（wt）转移性结直肠癌（mCRC）患者（pts）的一线治疗：IMPROVE研究
标题：Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
报告人：Antonio Avallone, MD
单位：Istituto Nazionale Tumori Fondazione G. Pascale
05 摘要号：3504
STRATEGIC-1：不可切除的野生型KRAS/NRAS/BRAF转移性结直肠癌的多线治疗试验——随机开放标签III期研究GERCOR-PRODIGE。
标题：STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.
报告人：Benoist Chibaudel, MD
单位：Department of Medical Oncology, Franco-British Institute
06 摘要号：3505
改良FOLFOXIRI联合帕尼单抗（mFOLFOXIRI/PAN）对比mFOLFOX6/PAN作为不可切除RAS和BRAF野生型转移性结直肠癌（mCRC）患者的初始治疗：III期随机研究TRIPLETE的结果
标题：Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.
报告人：Chiara Cremolini, MD, PhD
单位：Department of Translational Research and New Technologies in Medicine and Surgery-Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana
07 摘要号：LBA3506
FOLFOXIRI+贝伐单抗对比FOLFOX/FOLFIRI+贝伐单抗治疗初始无法切除的结直肠癌肝转移（CRLM）和右侧和/或RAS/BRAF V600E突变原发肿瘤的患者：荷兰结直肠癌组的III期CAIRO5研究
标题：FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.
报告人：Cornelis J. A. Punt, MD, PhD
单位：University Medical Center Utrecht
08 摘要号：3508
阿替利珠单抗联合改良DCF（多西他赛，顺铂和5-氟尿嘧啶）作为转移性或局部晚期鳞状细胞肛门癌的一线治疗：随机II期研究SEARCE-PRODIGE 60
标题：Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.
报告人：Stefano Kim, MD
单位：Bourgogne-Franche Comté University, Department of Medical Oncology, Besançon University Hospital
壁报讨论
01 摘要号：3509
纳武利尤单抗联合FOLFOXIRI/贝伐单抗作为晚期结直肠癌RAS/BRAF突变（mut）患者一线治疗的II期研究：NIVACOR试验（GOIRC-03-2018）
标题：Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).
报告人：Angela Damato, MD
单位：Medical Oncology Unit, Azienda USL-IRCCS Reggio Emilia
02 摘要号：3510
纳武利尤单抗（NIVO）±伊匹木单抗（IPI）用于患有微卫星不稳定性高/错配修复缺陷（MSI-H/dMMR）转移性结直肠癌（mCRC）的患者：CheckMate 142研究的5年随访结果
标题：Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
报告人：Michael J. Overman, MD
单位：University of Texas MD Anderson Cancer Center and SWOG
03 摘要号：3511
新辅助纳武利尤单抗，伊匹木单抗和塞来昔布治疗pMMR和dMMR结肠癌：NICHE研究的最终临床分析
标题：Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
报告人：Yara L. Verschoor, MD
单位：Netherlands Cancer Institute
04 摘要号：LBA3513
卡培他滨联合放疗继以度伐利尤单抗（MEDI4736）作为直肠癌术前治疗的II期研究：PANDORA研究最终结果
标题：A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.
报告人：Stefano Tamberi, MD, PhD
单位：UOC Oncologia Ravenna, AUSL Romagna
05 摘要号：LBA3514
低位直肠癌的根治性放化疗：多中心II期临床试验的主要临床结果
标题：Curative chemoradiation for low rectal cancer: Primary clinical outcomes from a multicenter phase II trial.
报告人：Lars Henrik Jensen, MD, PhD
单位：Danish Colorectal Cancer Center South, Vejle University Hospital
06 摘要号：3515
对于局部晚期直肠癌伴MRI阴性周缘（PSSR）的患者，一期手术后选择性放化疗与常规术前放化疗的对比：一项多中心，随机，开放性，非劣效性的III期临床试验
标题：Primary surgery followed by selective radiochemotherapy versus conventional preoperative radiochemotherapy for patients with locally advanced rectal cancer with MRI-negative circumferential margin (PSSR): A multicenter, randomized, open-label, noninferiority, phase 3 trial.
报告人：丁克峰
单位：浙江大学医学院附属第二医院
07 摘要号：3516
腹腔镜辅助与开放手术治疗低位直肠癌（LASRE）的短期获益：一项多中心，随机，对照试验。
标题：Short-term outcomes of laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): A multicenter, randomized, controlled trial.
报告人：池畔
单位：福建医科大学附属协和医院
08 摘要号：3519
评估FOLFIRI+西妥昔单抗诱导治疗继以5-FU联合贝伐珠单抗换药维持治疗与FOLFIRI+西妥昔单抗继续治疗的随机研究：III期FIRE-4研究（AIO KRK-0114）的次要终点报告
标题：Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).
报告人：Stefano Tamberi, MD, PhD
单位：UOC Oncologia Ravenna, AUSL Romagna
10 摘要号：3520
帕尼单抗联合或不联合曲美替尼治疗晚期结直肠癌的抗EGFR再激发治疗的II期研究
标题：Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.
报告人：Christine Megerdichian Parseghian, MD
单位：The University of Texas MD Anderson Cancer Center
壁报展示
01 摘要号：3563
信迪利单抗（IBI 308）联合CAPEOX和贝伐珠单抗（BBCAPX）作为RAS突变、微卫星稳定、不可切除的转移性结直肠癌患者的一线治疗的II期临床试验
标题：A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.
报告人：房雪峰
单位：浙江大学医学院附属第二医院肿瘤内科，肿瘤防治教育部重点实验室
02 摘要号：3566
替雷利珠单抗联合西妥昔单抗和伊立替康治疗RAS野生型晚期结直肠癌患者的疗效和安全性：II期单臂研究的初步结果
标题：Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.
报告人：Xiaojing Xu
单位：复旦大学附属中山医院肿瘤内科
03 摘要号：3574
CPGJ602联合mFOLFOX6作为KRAS/NRAS/BRAF野生型转移性结直肠癌患者的一线治疗：一项随机II期研究。
标题：CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.
报告人：徐建明
单位：中国人民解放军总医院第五医学中心
04 摘要号：3577
卡瑞利珠单抗联合famitinib治疗转移性结直肠癌：一项开放标签，多中心II期篮式研究的结果。
标题：Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.
报告人：刘天舒
单位：复旦大学附属中山医院肿瘤内科
05 摘要号：3594
双周mXELIRI对比FOLFIRI联合贝伐珠单抗作为转移性结直肠癌的一线治疗（EXIST）：一项多中心，随机，开放标签的II期研究
标题：Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
报告人：Zhichao Jiang
单位：中国医学科学院北京协和医学院肿瘤医院肿瘤研究所（国家癌症中心）
06 摘要号：3609
PKUCH 04试验：全程新辅助放化疗联合新辅助PD-1抑制剂治疗pMMR/MSS局部晚期的中低位直肠癌
标题：PKUCH 04 trial: Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for pMMR/MSS locally advanced middle to low rectal cancer.
报告人：武爱文
单位：北京大学肿瘤医院
07 摘要号：3611
全程新辅助放化疗联合新辅助PD-1抑制剂治疗pMMR、高危局部晚期中低位直肠癌患者
标题：Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for patients with pMMR, high-risk, and locally advanced middle to low rectal cancer.
报告人：武爱文
单位：北京大学肿瘤医院
参考来源：https://meetings.asco.org/meetings/2022-asco-annual-meeting